Hospital Acquired Disease Testing Market

Report Description
Table of Contents

Report Description

The global hospital-acquired disease testing market size is estimated to be USD 1,500.4 million in 2021 and is expected to witness a CAGR of 20.81% during the forecast period. Increasing incidences of different medical conditions are a key driver for the growth of the global hospital-acquired disease testing market. Additionally, growing length of stay in the hospital, negligence by the hospital staff during the patient’s stay, and increase in multi-drug resistant organisms (MDROs) are some of the other drivers propelling the market growth. Nevertheless, limited insurance coverage for such diseases and the presence of ambiguous management frameworks are expected to restrain the global market growth.

Global Hospital-Acquired Disease Testing Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Test Type

Based on test type, the market is segmented into pneumonia stents, urinary tract infection, bloodstream infection, surgical site infection, methicillin-resistant staphylococcus aureus, and others. In 2021, the urinary tract infection segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the factor stating that UTI is the most common hospital-acquired disease worldwide. Surgical site infection segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to negligence on part of the hospital staff during the patient’s stay.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the growing aged population, strict regulatory norms, improving healthcare infrastructure, and the increase in number of hospital stays along with the growing risk of contracting hospital-acquired disease. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, escalating demand for advanced medication and treatment, and growing medical tourism in this region.

Competitor Insights

Some of the key players in the hospital-acquired disease testing market are Luminex Corporation (U.S.); Diatherix Laboratories (U.S.); Life Technologies (U.S.); Cantel Medical Corporation (U.S.); Meridian Biosciences Inc. (U.S.); Nordion Inc. (Canada); Qiagen GmbH (Germany); Hoffmann-La Roche AG (Switzerland); Biomérieux (France); and Cepheid Inc. (U.S.). The leading players operating in the hospital-acquired disease testing industry are adopting various strategies including R&D investments, adoption of advanced techniques, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The hospital-acquired disease testing market report is categorized into the following segments and subsegments: